Neurocrine biosciences provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones

San diego, jan. 8, 2021 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of ingrezza® (valbenazine) for 2020, and key commercial and clinical development...

NBIX Ratings Summary

NBIX Quant Ranking